Loading…
Lobbying Spend
$18.7M
Filings
93
Firms Hired
1
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3 Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule, implementation, and legislation Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the elife sciences ecosystem Oppose drug importation proposals Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance Support capping Medicare beneficiary out of pocket costs Support expanded access to telehealth Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input
Client expense: $170,000 · Firm income: —
Matched citations: H.R. 3
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3 Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule final rule implementation, and legislation Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Oppose drug importation proposals Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance Support capping Medicare beneficiary out of pocket costs Support expanded access to telehealth Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule
Client expense: $170,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2022 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule implementation, and legislation. Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem. Oppose drug importation proposals. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance. Support capping Medicare beneficiary out of pocket costs. Support expanded access to telehealth. Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $180,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2022 · third_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule final rule implementation, and legislation. Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem. Oppose drug importation proposals. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance. Support capping Medicare beneficiary out of pocket costs. Support expanded access to telehealth. Support value-based purchasing provision, but opposed line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $170,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2022 · second_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule final rule implementation, and legislation. Oppose legislative proposal to reform Patent system and Intellectual Property issues negatively impacting the life sciences ecosystem. Oppose drug importation proposals. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance. Support expanded access to telehealth. Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $190,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2022 · first_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule final rule implementation, and legislation. Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem. Oppose drug importation proposals. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance. Support expanded access to telehealth. Support value-based purchasing provision, but opposed line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $200,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R.3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule implementation, and legislation. Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem. Oppose drug importation proposals. Support temporary home administration of Medicare Part B infused and injectable medicines during the COVID-19 public health emergency. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance. Support separate reimbursement structure for novel antibiotics to incentivize Research & Development. Support Medicare coverage of remote patient monitoring services. Oppose prior authorization requirements in Medicare Advantage. Support expanded access to telehealth. Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $190,000 · Firm income: —
Matched citations: H.R.3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule implementation, and legislation. Oppose drug importation proposals. Support temporary home administration of Medicare Part B infused and injectable medicines during the COVID-19 public health emergency. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance. Support separate reimbursement structure for novel antibiotics to incentivize Research & Development. Support Medicare coverage of remote patient monitoring services. Oppose prior authorization requirements in Medicare Advantage. Support expanded access to telehealth. Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $160,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · second_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule final rule implementation, and legislation. Oppose drug importation proposals. Support temporary home administration of Medicare Part B infused and injectable medicines during the COVID-19 public health emergency. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance. Support separate reimbursement structure for novel antibiotics to incentivize Research & Development. Support Medicare coverage of remote patient monitoring services. Oppose prior authorization requirements in Medicare Advantage. Support expanded access to telehealth. Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $110,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · first_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule implementation, and legislation. Oppose drug importation proposals. Support temporary home administration of Medicare Part B infused and injectable medicines during the COVID-19 public health emergency. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance. Support separate reimbursement structure for novel antibiotics to incentivize Research & Development. Support Medicare coverage of remote patient monitoring services. Oppose prior authorization requirements in Medicare Advantage. Support expanded access to telehealth. Support value-based purchasing provision, but opposed line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.
Client expense: $135,000 · Firm income: —
Matched citations: H.R. 3
Generating Antibiotic Incentives Now Act of 2011
2012 · second_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns regarding uncertainty and unpredictability of FDA drug and device regulatory environment. Support drug and device user fee legislation. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act.
Client expense: $150,000 · Firm income: —
Matched citations: HR 2182
Generating Antibiotic Incentives Now Act of 2011
2012 · first_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns regarding uncertainty and unpredictability of FDA drug and device regulatory environment. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act.
Client expense: $120,000 · Firm income: —
Matched citations: HR 2182
Generating Antibiotic Incentives Now Act of 2011
2011 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with increasing uncertainty and unpredictability of FDA drug and device regulatory environment. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act.
Client expense: $180,000 · Firm income: —
Matched citations: HR 2182
Life Sciences Jobs and Investment Act of 2011
2011 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support Life Sciences Job & Investment Act (HR 2632). Support repeal of medical device tax. Support extension of Therapeutic Discovery Project program. Support extension of R&D tax credit.
Client expense: $180,000 · Firm income: —
Matched citations: HR 2632
Generating Antibiotic Incentives Now Act of 2011
2011 · third_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl changes to 510(k) process. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act. Support HR2405, PAHPA Reauthorization.
Client expense: $140,000 · Firm income: —
Matched citations: HR 2182
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
2011 · third_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl changes to 510(k) process. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act. Support HR2405, PAHPA Reauthorization.
Client expense: $140,000 · Firm income: —
Matched citations: HR2405
Life Sciences Jobs and Investment Act of 2011
2011 · third_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support extension of the R&D tax credit. Support repeal of medical device tax. Support HR 2632, the Life Sciences Jobs and Investment Act.
Client expense: $140,000 · Firm income: —
Matched citations: HR 2632
Regenerative Medicine Promotion Act of 2011
2011 · second_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support HR 1862, the Regenerative Medicine Promotion Act. Support NIH funding.
Client expense: $180,000 · Firm income: —
Matched citations: HR 1862
Generating Antibiotic Incentives Now Act of 2011
2011 · second_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl changes to 510(k) process. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act.
Client expense: $180,000 · Firm income: —
Matched citations: HR 2182
To extend the temporary suspension of duty on certain nickel-metal hydride storage batteries designed for use in hybrid vehicles.
2010 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support HR 5116/S 3605, America COMPETES Act Reauthorization.
Client expense: $205,000 · Firm income: —
Matched citations: HR 5116
To extend the temporary suspension of duty on certain nickel-metal hydride storage batteries designed for use in hybrid vehicles.
2010 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support HR 5116/S 3605, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.
Client expense: $205,000 · Firm income: —
Matched citations: HR 5116
Patent Reform Act of 2009
2010 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value; Support efforts to address impact of recent court ruling re patent false markings suit
Client expense: $205,000 · Firm income: —
Matched citations: HR 1260
America Creating Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science Reauthorization Act of 2010
2010 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support HR 5116/S 3605, America COMPETES Act Reauthorization.
Client expense: $205,000 · Firm income: —
Matched citations: S 3605
America Creating Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science Reauthorization Act of 2010
2010 · fourth_quarter · Firm: CALIFORNIA LIFE SCIENCES
Support HR 5116/S 3605, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.
Client expense: $205,000 · Firm income: —
Matched citations: S 3605
Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value; Support efforts to address impact of recent court ruling re patent false markings suit
Client expense: $205,000 · Firm income: —
Matched citations: S 515
Source: Senate LDA